Learning more about MS and Rare Autoimmune Diseases like NMOSD and MOGAD
#NMOSD #MOGAD #MS #autoimmune #raredisease…
Town Hall Meeting – New Frontier of Multiple Sclerosis, treatments and more
Listen and learn with Dr. Aaron Boster, MD #Sanofi #Sandoz…
Stuart Schlossman
Yes, I LIVE and BREATHE MULTIPLE SCLEROSIS
I found a way to overcome the grief of learning my condition in 1998, and turned it into a positive…
Stuart Schlossman
A LOOK at Holistic & Mainstream Approaches to Multiple Sclerosis
No excerpt…
Stuart Schlossman
Treating Multiple Sclerosis: Are They Doing It Wrong?
@AaronBosterMD Click red box to activate this video…
Stuart Schlossman
PRESS RELEASE : Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis
Paris, December 13, 2024. The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of…
Stuart Schlossman
Gabapentinoids, yet another dirty secret
Some people with MS are on ten or more concomitant medications including gabapentin or pregabalin. Are you? Gavin Giovannoni –…
Stuart Schlossman
Let’s Move From Categorizing MS by Clinical Phenotype to Underlying Disease Mechanisms
September 19, 2024 – Meaningful characterization is critical to advancing research and care, review authors contend The currently used phenotypic…
Stuart Schlossman
New Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch patients
Sep 18, 2024 East Hanover, September 18, 2024 – Novartis today announced new data from the ALITHIOS open-label extension study. Data…
Stuart Schlossman
Press Release: FDA Approves Ocrevus Zunovo™ as the First and Only Twice-a-Year 10-Minute Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis
Ocrevus Zunovo™ has the potential to expand treatment options to centers without IV infrastructure or with IV constraints, like at a…
Stuart Schlossman
